96 results on '"Yang, J.C."'
Search Results
2. OA21.06 ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
3. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
4. OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
5. PL03.13 Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2)
6. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer
7. OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors
8. P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION
9. OA04.04 The Registry of Genetic Alterations of Taiwan NSCLC by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study - TCOG T1521 Study
10. 161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)
11. 30 Long-term efficacy, safety, and predictors of response to amivantamab among patients with post-platinum EGFR Ex20ins-mutated advanced NSCLC
12. Device processing and junction formation needs for ultra-high power Ga2O3electronics
13. 29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors
14. EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
15. EP08.02-029 Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
16. OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
17. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
18. P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
19. P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
20. P01.01 LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RETFusion-Positive NSCLC
21. FP16.03 Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
22. EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
23. EP08.01-028 Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
24. OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
25. OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
26. Research of the Cylinder Wire Front Angle of Cotton Combing Frame
27. OA15.02 Phase 1 Studies of DZD9008, an Oral Selective EGFR/HER2 Inhibitor in Advanced NSCLC with EGFR Exon20 Insertion Mutations
28. P45.06 Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
29. FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy
30. PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
31. OA03.09 Overall Survival in Patients with EGFRM+ NSCLC Receiving Sequential Afatinib and Osimertinib: an Update of the Giotag Study
32. OA11.01 Complex EGFR Mutations in Lung Adenocarcinoma
33. ES18.02 When to Switch to a New TKI : Imaging Based Crtieria or Positive Liquid Biopsy?
34. P2.14-20 ATORG-003: Dacomitinib With or Without Dose Titration as First-Line Therapy for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)
35. Angiogenesis is not Mediated by Prostate Cancer Neuropeptides
36. A Catalyst to Change Everything: MEMS/NEMS – a Paradigm of Taiwan's Nanotechnology Program
37. ORGANIC-INORGANIC HYBRID MATERIALS 6: NMR STUDY OF THE POLYVINYLIMIDAZOLE-SILICA HYBRIDS
38. Reduced gravity combustion of thermoplastic spheres1
39. Relative stability of subcooled flow boiling on non-uniformly heated, inclined flat surface
40. 185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)
41. Novel interactions of supported clusters: contact epitaxy
42. Boiling stability characteristics of methanol flowing over a nonuniformly heated surface
43. Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach
44. Degradation of some poly(methylphenylsiloxane)-poly(methyl methacrylate) interpenetrating polymer networks
45. Multi-Terminal Binary Decision Diagrams: An Efficient Data Structure for Matrix Representation
46. Production of a cell wall‐specific monoclonal antibody to Fibrobacter succinogenes
47. Effect of Organic Additive on the Preparation of Rutile TiO2by Steam Treatment
48. Sintering and oxidation using a novel ultrahigh vacuum transmission electron microscope with in situ magnetron sputtering
49. Percutaneous trans-hepatic cholangioscopy and lithotripsy in the treatment of intrahepatic stones: a study with 5 year follow-up
50. Techniques for Studying Nanoparticle Sintering by Plan-View In Situ Transmission Electron Microscopy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.